Application based on DESTINY-Breast03 results showing Daiichi Sankyo and AstraZeneca’s trastuzumab deruxtecan reduced risk of disease progression or death by 72% versus trastuzumab emtansine (T-DM1)
The single-dose vaccine has been approved in China, Mexico, Ecuador, Chile, Argentina, Hungary, Kirghizstan, Pakistan, Indonesia and Malaysia
SAGE recommends additional third dose of the vaccine administered to immunocompromised persons
Sputnik Light as a booster significantly increases virus neutralizing activity against Omicron based on sera 2-3 months after revaccination
These results demonstrate the potential benefits of heterologous boosting (mix-and-match). The article describing these results have been posted on medRxiv
Going forward, the fastest-growing regions in the generic pharmaceuticals market will be South America and the Middle East, where growth will be at CAGRs of 10.1% and 9.4% respectively
ALASTIN’s patented, differentiated technology and products are highly synergistic with Galderma’s premium portfolio
_256_384.jpg)
Destiny-Breast11 will evaluate Enhertu as a monotherapy or Enhertu followed by paclitaxel, trastuzumab and pertuzumab
One-shot Sputnik Light is a highly effective vaccine when used both on standalone basis and applied as a booster
The nutraceutical sector is on the cusp of exponential growth and Covid-19 has accelerated the pace of its applications. Dr R.B Smarta, CMD, Interlink, shares his perspective on the growth opportunities and challenges for the sector
Subscribe To Our Newsletter & Stay Updated
